CEO Alexander Macrae stated that "Sangamo continued to make significant pipeline progress in 2025 and into the first quarter of '26. Set against a backdrop of regulatory and market uncertainty and ...
Good afternoon, and welcome to the Sangamo Therapeutics Fourth Quarter and Full Year 2025 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the ...
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Hayleigh Collins: A copy of this press release is available on the company’s website and through our SEC filings. Joining me on today’s call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief ...
On Tuesday, March 10, 2026, PolyPid (NASDAQ:PYPD) presented at The Citizens Life Sciences Conference 2026, highlighting its strategic initiatives and future plans. The conference call underscored the ...
Earnings call Ocugen reported increased R&D spending and a wider net loss year-over-year as it accelerated late-stage gene therapy programs, completed key trial enrollments, and secured new licensing ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results